INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
INOVIO (NASDAQ:INO) will release its second quarter 2022 financial results on August 9, 2022, after market close. Following the release, the company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the results and provide an update on its business. Focused on DNA medicines for infectious diseases and cancer, INOVIO utilizes a proprietary smart device for vaccine delivery. For more information, visit www.inovio.com.
Details
News Market Reaction – INO
The recorded move for INO in the trading session of this news was +1.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PLYMOUTH MEETING, Pa., July 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. EDT to discuss financial results and provide a general business update.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines are delivered using our proprietary smart device to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Contacts
Investors & Media:
Gene Kim, (267) 589-9471, gene.kim@inovio.com
Thomas Hong, (267) 440-4298, thomas.hong@inovio.com
View original content:https://www.prnewswire.com/news-releases/inovio-to-report-second-quarter-2022-financial-results-on-august-9-2022-301593136.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.